Stifel Nicolaus Raises Enfusion (NYSE:ENFN) Price Target to $13.00

Enfusion (NYSE:ENFN) had its price target increased by Stifel Nicolaus from $11.00 to $13.00 in a research note released on Wednesday,Benzinga reports. The brokerage currently has a buy rating on the stock.

Enfusion Stock Performance

Shares of NYSE ENFN opened at $10.63 on Wednesday. Enfusion has a 52-week low of $7.52 and a 52-week high of $11.38. The stock has a market cap of $1.37 billion, a P/E ratio of 265.82, a P/E/G ratio of 3.98 and a beta of 0.97. The firm has a 50 day moving average price of $9.70 and a 200 day moving average price of $9.00.

Insider Buying and Selling

In other Enfusion news, COO Neal Pawar sold 21,801 shares of Enfusion stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $10.03, for a total value of $218,664.03. Following the transaction, the chief operating officer now owns 1,143,544 shares of the company’s stock, valued at approximately $11,469,746.32. The trade was a 1.87 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 36.44% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Enfusion

Large investors have recently made changes to their positions in the stock. RiverPark Advisors LLC bought a new stake in Enfusion in the 2nd quarter valued at $68,000. Arizona State Retirement System acquired a new stake in shares of Enfusion in the 2nd quarter valued at about $86,000. Harbor Capital Advisors Inc. lifted its holdings in shares of Enfusion by 12.4% in the third quarter. Harbor Capital Advisors Inc. now owns 11,887 shares of the company’s stock valued at $113,000 after purchasing an additional 1,315 shares in the last quarter. Belvedere Trading LLC acquired a new position in shares of Enfusion during the third quarter worth about $114,000. Finally, Paloma Partners Management Co bought a new position in shares of Enfusion during the third quarter worth about $157,000. Institutional investors own 81.05% of the company’s stock.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.